Price
$20.27+14.46%Social Signal Score
Analyst Ratings
9 analystsRevenue
$324.16M+137.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Franco Stevanato
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 6,010
- Beta
- 0.80
- Country
- IT
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.64
Financials
Revenue
$324.16M+137.6%Net Income
$41.55M+467.3%EBITDA
$82.41M+233.4%Free Cash Flow
$24.37MEPS (diluted)
$0.16+545.2%Shares Outstanding (diluted)
273.10M-7.4%Operating Expenses
$37.48MCash & Debt
$116.04MReturn of Capital
$14.65MDividend per Share
$0.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.14B | $134.28M | $0.49 |
| 2024 | $1.10B | $117.78M | $0.43 |
| 2023 | $1.09B | $145.63M | $0.55 |
| 2022 | $983.68M | $142.85M | $0.53 |
| 2021 | $843.92M | $134.32M | $0.53 |
| 2020 | $662.04M | $78.51M | $0.28 |
| 2019 | $536.54M | $39.20M | $0.15 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from STVN's reported EPS growth of 21.8% a year over 6 years.
- EPS in 5 years
- $1.32
- Implied price
- $46.15
- Return from $15.65
- 24.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.94 — today's price is already 31.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| 11.8% | 6.5% | 10.5% | 14.0% | 17.0% | 19.8% |
| 16.8% | 11.3% | 15.4% | 19.0% | 22.3% | 25.2% |
| 21.8% | 16.1% | 20.4% | 24.1% | 27.5% | 30.5% |
| 26.8% | 20.8% | 25.3% | 29.2% | 32.7% | 35.9% |
| 31.8% | 25.6% | 30.3% | 34.3% | 38.0% | 41.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (11)
- Newsbusinesswire.com·15d ago·Negative
STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $STVN--STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C. Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Stevanato Group (STVN) investors following the Company's stock price decline
View source ↗ - Newsmarketbeat.com·18d ago·Negative
Stevanato Group Q3 Earnings Call Highlights Stevanato Group NYSE: STVN reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A. STVN shares fell on November 3, 2026, as the market reacted to a lower GLP-1 revenue outlook in Stevanato Group's pre-market third-quarter results, the issue previews had flagged as the quarter's key test. SueWallSt notifies investors of a pending investigation into whether the Company's disclosures to investors met U.S. securities law requirements.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript Stevanato Group S.p.A. ( STVN ) Q3 2026 Earnings Call November 3, 2026 8:30 AM EST Company Participants Lisa Miles - Chief Communications & Investor Relations Officer Franco Stevanato - CEO & Executive Chairman Marco Dal Lago - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Avantika Dhabaria - BofA Securities, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Rese…
View source ↗ - Newszacks.com·19d ago·Positive
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates Stevanato Group (STVN) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.
View source ↗ - Newsbusinesswire.com·19d ago·Negative
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €326.1 million, and on an or…
View source ↗ - Newsbusinesswire.com·33d ago·Negative
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a …
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsgurufocus.com·86d ago·Negative
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors On August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to
View source ↗ - Newsmarketbeat.com·105d ago·Negative
Stevanato Group Q2 Earnings Call Highlights Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $0.22 per share
Typical surprise +9.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.18 vs $0.18beat
- Tue, Aug 4$0.16 vs $0.14beat
- Thu, May 7$0.13 vs $0.12beat
- Wed, Mar 4$0.21 vs $0.20beat
- Thu, Nov 6$0.16 vs $0.14beat
- Tue, Aug 5$0.12 vs $0.11beat
Estimates and results for STVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STVN officers and directors.
- Bought
- $601k
- Sold
- $562k
2 trades
8 trades
- Federici William Jbought
- Morel Donald E Jrbought
- Stocchi Maurosold
- Santel Lucianosold
- Dal Lago Marcosold
- Magistretti Elisabettasold
- Balachandran Madhavansold
- Morel Donald E Jrsold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
